Table 3.
Late toxicity in the second cohort from the assessment at the time of analysis
| Toxicity | CF-PMRT n (%) N = 457 |
HF-PMRT n (%) N = 480 |
p-value |
|---|---|---|---|
| Skina | < 0.001 | ||
| Grade 0 | 197 (43) | 340 (71) | |
| Grade 1 | 255 (56) | 122 (25) | |
| Grade 2 | 5 (1) | 9 (2) | |
| Grade 3 | 0 (0) | 9 (2) | |
| Subcutaneous tissuea | < 0.001 | ||
| Grade 0 | 261 (57) | 370 (77) | |
| Grade 1 | 185 (41) | 75 (16) | |
| Grade 2 | 11 (2) | 35 (7) | |
| Lung (Clinical)a | < 0.001 | ||
| Grade 0 | 389 (85) | 239 (50) | |
| Grade 1 | 62 (14) | 240 (50) | |
| Grade 2 | 6 (1) | 1 (< 1) | |
| Lung (Imaging)a | < 0.001 | ||
| Grade 0 | 184 (40) | 249 (52) | |
| Grade 1 | 199 (44) | 187 (39) | |
| Grade 2 | 24 (5) | 7 (1) | |
| Grade 3 | 50 (11) | 37 (8) | |
| Hearta | 0.840 | ||
| Grade 0 | 453 (99) | 477 (99) | |
| Grade 1 | 0 (0) | 0 (0) | |
| Grade 2 | 1 (< 1) | 0 (0) | |
| Grade 3 | 3 (< 1) | 3 (< 1) | |
| Lymphedemab | 0.905 | ||
| Stage 0 | 442 (97) | 467 (97) | |
| Stage 1 | 11 (2) | 9 (2) | |
| Stage 2 | 4 (1) | 4 (1) | |
| Brachial Plexopathyc | < 0.001 | ||
| Grade 0 | 421 (92) | 469 (98) | |
| Grade 1 | 36 (8) | 11 (2) |